U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936084) titled 'Clinical Trial of GenSci136 in Patients With Myasthenia Gravis' on Oct. 27.
Brief Summary: Phase Ib/II Clinical Trial of GenSci136 in Patients with Myasthenia Gravis
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Patients With MG (gMG and oMG)
Intervention:
DRUG: GenSci136 for injection
GenSci136 for injection, administered the medication according to the requirements of the protocal
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....